Skip to main content
Premium Trial:

Request an Annual Quote

Reprogen Closes on $6.5 Million Private Financing, Appoints CFO

Premium

IRVINE, Calif.--Reprogen, a privately held functional genomics company here with a focus on reproductive medicine, announced the second closing of $1.4 million in a private financing round. The company announced the first closing of this round in February at $5.1 million. New participants included a Munich-based venture capital fund, Life Science Ventures, and Hambrecht and Quist. Reprogen CEO Jeffrey Miller said the financing provides a foundation for Reprogen to continue to enhance its three proprietary technologies. "These platforms enable us to efficiently identify and characterize novel drug targets involved in reproductive diseases," Miller said.

Miller credits Reprogen's new chief financial officer and vice-president of finance and administration, Sharon Tetlow, with bringing high-quality investors to its second closing. Tetlow, formerly of Terrapin Technologies, Synergen, Genentech, and Eli Lilly, brings 12 years' pharmaceutical and biotech experience to Reprogen. She holds an MBA from Stanford University.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.